TKMR News 23.90 10/16/2014 05:49:54 Tekmira Pharmaceuticals Corp

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Tekmira Pharmaceuticals Corp (TKMR) 23.90 $TKMR

Ebola Viral Infections Therapeutics Pipeline Review, H2 2014 Report - 23 Companies & 30+ Drug Profiles
M2 - 16 mins ago
Research and Markets (http://www.researchandmarkets.com/research/mzj43q/ebola_viral) has announced the addition of the "Ebola Viral Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola Viral Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Ebola Viral Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Ebola Viral Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Ebola Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Ebola Viral Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Tekmira Pharmaceuticals Corp. - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Toyama Chemical Co., Ltd. - Crucell N.V. - Medicago Inc. - NanoViricides, Inc. - BioCryst Pharmaceuticals, Inc. - Summit Corporation plc - AlphaVax, Inc. - Chimerix, Inc. - Microbiotix, Inc. - Immunovaccine, Inc. - Integrated BioTherapeutics, Inc. - Vaxart, Inc. - Profectus BioSciences, Inc. - Navigen Pharmaceuticals, Inc. - Inhibikase Therapeutics, Inc. - Humabs BioMed SA - Mapp Biopharmaceutical, Inc. - NewLink Genetics Corporation - Epirus Biopharmaceuticals, Inc. Drug Profiles - Recombinant Vector Vaccine for Multivalent Filovirus - TKM-100802 - brincidofovir - favipiravir - Filovirus Vaccine - Drugs for Ebola and Marburg Infections - SMT-15000 - panfilovirus vaccine - BCX-4430 - ET-007 - ZMapp - Polyvalent DNA Vaccine for Ebola and Marburg Filoviruses - ZMAb - MVA-BN-Filoviruses Vaccine - ebola virus vaccine - ebola and marburg vaccine (trivalent) - TKM-100701 - MMCatLMC - ebola and marburg rabies vaccine - Monoclonal Antibodies for Viral Infections - imatinib mesylate - oxocarbazate - thiocarbazate - EMER-IT - Ebola Vaccine - Synthetic Peptides for Ebola Virus - Monoclonal Antibodies for Ebola and Marburg Infections - ARD-5 - 1-E703 For more information visit http://www.researchandmarkets.com/research/mz...bola_viral
INO: 11.24 (+0.30), BCRX: 11.96 (+1.53), CMRX: 32.18 (+3.13), NLNK: 25.44 (+3.61), TKMR: 23.90 (+0.30), NNVC: 3.68 (-0.01), GSK: 43.13 (-0.55)

Tekmira Presents Results of Preclinical Studies With Hepatitis B Therapeutic
GlobeNewswire - Wed Oct 15, 2:30PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today the presentation of preclinical results characterizing TKM-HBV, a therapeutic agent targeting human hepatitis B virus (HBV), at the 10 Annual Meeting of the Oligonucleotide Therapeutics Society. Tekmira's Chief Technical Officer, Dr. Ian MacLachlan delivered a podium presentation titled, "Update on the Preclinical Development of an LNP-Based HBV Therapeutic." The conference is taking place in San Diego, California, from October 12 - 15, 2014.
TKMR: 23.90 (+0.30), TKM.TO: 26.70 (+0.02)

Critical Alerts For Tesla Motors, Tekmira Pharmaceuticals, Gilead Sciences, 3D Systems and TASER International Released By InvestorsObserver
PR Newswire - Wed Oct 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TSLA, TKMR, GILD, DDD and TASR.
TSLA: 229.70 (+2.64), GILD: 96.16 (-1.02), DDD: 41.27 (+0.25), TKMR: 23.90 (+0.30), TASR: 14.69 (+0.49)

Technical Scrutiny on Health Care Sector Stocks - ImmunoGen, Arrowhead Research, Chimerix, Tekmira Pharma, and Celgene
PR Newswire - Wed Oct 15, 8:10AM CDT
Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. (NASDAQ: IMGN), Arrowhead Research Corporation (NASDAQ: ARWR), Chimerix Inc. (NASDAQ: CMRX), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), and Celgene Corporation (NASDAQ: CELG). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Tuesday, October 14, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 16,315.19, down 0.04% and the NASDAQ Composite closed at 4,227.17, up 0.32%. The S&P 500 finished the session 0.16% higher at 1,877.70. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 705.81, down 0.76%, whereas the index has advanced 9.89% on YTD basis. Register for your complimentary reports on these five stocks at:
CMRX: 32.18 (+3.13), ARWR: 6.47 (+0.59), IMGN: 8.76 (+0.09), TKMR: 23.90 (+0.30), CELG: 86.55 (+0.07)

Tekmira provides encouraging clinical data for LNP-Enabled Patisiran at the American Neurological Association's 2014 Annual Meeting
M2 - Tue Oct 14, 7:23AM CDT
Biopharmaceutical company Tekmira Pharmaceuticals (NasdaqCM:TKMR) (TSX:TKM.TO) pn Tuesday announced its six-month clinical data for the ongoing Patisiran Phase II Open Label Extension (OLE) study in patients with Familial Amyloidotic Polyneuropathy (FAP).
ALNY: 84.39 (+1.44), TKMR: 23.90 (+0.30)

Tekmira's Partner Reports Positive Clinical Data for LNP-Enabled Patisiran
GlobeNewswire - Mon Oct 13, 11:45PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported that Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) presented six-month clinical data for the ongoing Patisiran Phase II Open Label Extension (OLE) study in patients with Familial Amyloidotic Polyneuropathy (FAP). Patisiran (ALN-TTR02) is an RNAi therapeutic targeting transthyretin (TTR) in development for the treatment of TTR-mediated amyloidosis (ATTR), which is enabled by Tekmira's lipid nanoparticle (LNP) technology.
ALNY: 84.39 (+1.44), TKMR: 23.90 (+0.30), TKM.TO: 26.70 (+0.02)

Is the U.S. Prepared to Handle Ebola?
Todd Campbell, The Motley Fool - Motley Fool - Sun Oct 12, 12:45PM CDT
Source: National Nurses United  The passing of Eric Duncan, the first patient diagnosed with Ebola in the U.S., 10 days after being admitted to Texas Health Presbyterian Hospital, is a stark reminder of Ebola's insidious nature. It's a tough to...
CAH: 73.23 (-1.35), KMB: 105.41 (-1.00), TKMR: 23.90 (+0.30), SRCL: 116.15 (-1.43), GSK: 43.13 (-0.55), OMI: 32.18 (-0.23)

'Fast Money' Recap: How to Trade in a Volatile Marketplace
at The Street - Fri Oct 10, 4:00AM CDT
The trading panel discussed defensive trades, the state of the market and whether Carl Icahn is right about Apple.
TSLA: 229.70 (+2.64), LO: 58.72 (-0.82), XOM: 90.22 (-0.33), TKMR: 23.90 (+0.30), PANW: 97.43 (+3.18), TLT: 122.53 (+0.96), PEP: 91.77 (-1.24), T: 33.87 (+0.03), CMRX: 32.18 (+3.13), RIG: 29.44 (+0.47), AAL: 31.69 (+0.18), GOOGL: 540.73 (-7.96), TWTR: 49.99 (+1.41), AAPL: 97.54 (-1.21), AMZN: 305.97 (-2.34), FB: 73.21 (-0.38), SYMC: 22.15 (-0.32), TOT: 55.28 (-0.77), TSO: 58.64 (-0.58), CVEO: 12.71 (+0.54), IWM: 106.60 (+1.06), GPS: 35.94 (-0.51), CVX: 109.27 (-0.51), GG: 23.64 (-0.07)

Chimerix Falls as Ebola Patient on Brincidofovir Dies in US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 3:30PM CDT
Chimerix 's (CMRX) brincidofovir failed to save the Ebola patient.
MDVN: 89.63 (-1.68), BCRX: 11.96 (+1.53), CMRX: 32.18 (+3.13), TKMR: 23.90 (+0.30)

Hazmat Suit Maker Lakeland Soars On Dallas Ebola Fear
at Investor's Business Daily - Thu Oct 09, 1:38PM CDT
Lakeland Industries (LAKE) shares soared Thursday after a Dallas County sheriff's deputy was put in isolation with possible Ebola symptoms, raising fears the deadly virus may be spreading in the U.S. The company makes the ChemMax 1 hazmat suit, which...
CMRX: 32.18 (+3.13), HEB: 0.33 (+0.01), NLNK: 25.44 (+3.61), TKMR: 23.90 (+0.30), LAKE: 23.60 (+2.17), GSK: 43.13 (-0.55)

Tekmira to Present HBV Pre-Clinical Data at Meeting of the Oligonucleotide Therapeutics Society
GlobeNewswire - Thu Oct 09, 12:00PM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that Dr. Ian MacLachlan, Tekmira's Executive Vice President and Chief Technical Officer, will present preclinical data for TKM-HBV, the Company's product candidate targeting hepatitis B virus, at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society. The presentation will take place on Wednesday, October 15, 2014 at 12 pm (PT) / 3 pm (ET) in San Diego at The Hilton San Diego Resort and Spa.
TKMR: 23.90 (+0.30), TKM.TO: 26.70 (+0.02)

'Fast Money Halftime Report': U.S. Stocks Rebound, but Traders Look for a Pullback
at The Street - Wed Oct 08, 2:44PM CDT
The trading panel discusses energy and retail stocks, as well as whether the market has further downside ahead. GM CEO Mary Barra, a guest, talked about GM's future.
GPRO: 72.87 (-2.16), DFE: 48.66 (+0.05), F: 13.62 (-0.16), DUK: 78.90 (+0.03), GBX: 49.48 (+1.86), DAL: 32.38 (-0.41), TKMR: 23.90 (+0.30), DIS: 82.08 (-2.06), SMH: 45.87 (-0.01), SHLD: 29.56 (+1.07), CMRX: 32.18 (+3.13), SRPT: 20.91 (+2.00), TGT: 59.98 (-1.71), JCP: 7.09 (-0.07), COST: 124.30 (-1.95), GM: 29.69 (-0.42), LAKE: 23.60 (+2.17), XLE: 80.56 (+0.61)

Stock Market Today: Stocks Spike as Fed Minutes Allay Fears of Rate Hike
at The Street - Wed Oct 08, 1:24PM CDT
U.S. stocks popped on Wednesday after the release of the Federal Reserve minutes which allayed fears an interest rate hike could come sooner than expected.
ACT: 217.24 (-4.83), VRX: 114.34 (-0.60), MON: 108.83 (+0.96), VMW: 89.57 (+0.14), WMT: 75.20 (-2.78), TKMR: 23.90 (+0.30), SHLD: 29.56 (+1.07), AGN: 177.59 (-4.40), GTAT: 0.44 (+0.03), CMRX: 32.18 (+3.13), JCP: 7.09 (-0.07), EMC: 27.27 (-0.34), AAPL: 97.54 (-1.21), YUM: 67.23 (-0.59)

Ebola Outbreak Puts the Spotlight on 10 Biotech Companies
at The Street - Wed Oct 08, 11:32AM CDT
The Ebola outbreak has put the spotlight on Chimerix as well as other biotech companies with potential vaccines and even those stocks with marginal relation to the virus.
INO: 11.24 (+0.30), BCRX: 11.96 (+1.53), CMRX: 32.18 (+3.13), HEB: 0.33 (+0.01), SRPT: 20.91 (+2.00), NLNK: 25.44 (+3.61), TKMR: 23.90 (+0.30), LAKE: 23.60 (+2.17), GSK: 43.13 (-0.55)

Tekmira Pharmaceuticals (TKMR) Is Strong On High Volume Today
at The Street - Wed Oct 08, 10:35AM CDT
Trade-Ideas LLC identified Tekmira Pharmaceuticals (TKMR) as a strong on high relative volume candidate
TKMR: 23.90 (+0.30)

The Disgusting Reaction to Ebola Patient's Death by Tekmira, Chimerix Traders
at The Street - Wed Oct 08, 10:33AM CDT
Tekmira shares surge after Thomas Duncan's death announced.
CMRX: 32.18 (+3.13), TKMR: 23.90 (+0.30)

Revised Guidance, Development Milestones, Appointment, Program Extension, and Event Schedules - Research Reports on Mylan, Tekmira, GSK, Cigna and WellPoint
PR Newswire - Wed Oct 08, 8:00AM CDT
Today, Analysts Review released its research reports regarding Mylan, Inc. (NASDAQ: MYL), Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR), GlaxoSmithKline plc (NYSE: GSK), Cigna Corp. (NYSE: CI) and WellPoint Inc. (NYSE: WLP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7013-100free.
CI: 88.73 (+1.02), TKMR: 23.90 (+0.30), MYL: 47.38 (+0.56), GSK: 43.13 (-0.55), WLP: 111.06 (-2.14)

'Fast Money' Recap: What Should You Buy in a Declining Market?
at The Street - Wed Oct 08, 4:00AM CDT
The trading panel discusses Yum! Brands, the mining industry and Ebola treatments.
PEI: 19.15 (-0.09), CLR: 53.85 (+1.11), GMCR: 139.61 (+0.96), TKMR: 23.90 (+0.30), IBB: 256.47 (+1.20), M: 56.00 (-0.58), JBLU: 10.30 (+0.07), UPS: 96.45 (+0.65), PEP: 91.77 (-1.24), SBUX: 72.38 (-0.36), AGN: 177.59 (-4.40), SAVE: 53.97 (-1.40), CMRX: 32.18 (+3.13), EOG: 88.17 (+4.33), DPZ: 83.65 (-0.65), COST: 124.30 (-1.95), GOOGL: 540.73 (-7.96), CMLS: 3.29 (+0.12), AAPL: 97.54 (-1.21), MBLY: 45.35 (+0.72), YUM: 67.23 (-0.59), APC: 85.46 (+0.80), AMBA: 38.60 (+2.94), AEC: 18.61 (+0.06), GPRO: 72.87 (-2.16), ETN: 58.97 (-0.08), IR: 53.94 (-0.14), GSK: 43.13 (-0.55), PXD: 171.58 (+6.80), MCD: 90.44 (-0.66), GM: 29.69 (-0.42), IWM: 106.60 (+1.06), SODA: 21.21 (+0.26)

Nasdaq stocks posting largest percentage decreases
AP - Tue Oct 07, 6:00PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
TTS: 8.62 (-0.04), OLED: 30.08 (+1.84), EZPW: 9.39 (+0.44), CONN: 29.93 (+0.65), ADHD: 5.45 (-0.06), LINTB: 30.07 (+1.98), GWGH: 8.93 (+0.18), LINTA: 29.92 (+1.79), TKMR: 23.90 (+0.30), AEGN: 17.09 (+0.05), UCTT: 8.09 (+0.40), TKM.TO: 26.70 (+0.02)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s Second IND Adds Proof to Its Glue Platform

Updated Category News Views 25

Two IND acceptances from one long-running alliance is not nothing, especially in a drug-discovery business where plenty of polished platform talk never makes it to the clinic. Evotec has cleared that modest but meaningful bar again with Bristol Myers Squibb: a second molecular-glue candidate has received FDA acceptance for an Investigational New Drug application. The...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 125

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Miami I20 Tests Appetite for Long-Term U.S. Capital

Updated Category News Views 154

Five days in a Miami airport hotel may not sound like the machinery of national investment policy, yet the guest list for the inaugural I20 Summit is serious enough to make capital markets sit up. From December 11 through 15, the Sovereign Wealth Fund Institute plans to bring sovereign funds, pensions, endowments, family offices, business leaders and U.S....

Continue Reading
WeWalk Brings Diabetes Support Back to Dubai Science Park

Updated Category News Views 32

Before sunrise on 21 November, a 3.5 km route in Dubai Science Park will carry a purpose bigger than sneakers and weekend fitness. WeWalk is returning for its seventh edition, with TECOM Group PJSC and Dubai Charity Association again putting the event behind support for children living with diabetes. That deserves to be said plainly: this is a community health effort, not...

Continue Reading
Weatherford Adds Grant Roach to Its Sports Deal Team

Updated Category News Views 69

Sports investing has reached that awkward middle age where everybody sees the runway, but few can explain exactly where the bumps are. Weatherford Capital’s decision to bring Grant Roach aboard as vice president is not a headline packed with transaction fireworks. It is, however, a pretty clear tell: the Tampa firm intends to put more bodies and more underwriting muscle...

Continue Reading
Travelzoo Turns Thanksgiving Delays Into Member Value

Updated Category News Views 108

Airport gridlock is a miserable place to make a membership pitch, yet Travelzoo has found a pretty shrewd angle for it. On November 18, the company said nearly 20 million travelers will move through airports during the upcoming Thanksgiving holiday, when cancellations and delays can turn an ordinary trip into a long, fluorescent-lit slog. Its offer: qualifying Club...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 57

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
Adecco Finds AI Value Depends on Better Work Redesign

Updated Category News Views 39

A shiny AI license is not a productivity strategy, and Adecco's latest workforce survey puts some hard numbers behind that irritation. The company surveyed 40,500 workers in 36 countries for its seventh Global Workforce of the Future report, released November 19, 2026. Its central finding is disarmingly sensible: AI produces more when companies rebuild the work around it...

Continue Reading
CHN Energy's Indonesia Record Deserves a Hard Look

Updated Category News Views 50

Twenty years of boots sinking into swamp mud tells a sturdier story than a polished anniversary slogan. CHN Energy says it entered Indonesia's energy market two decades ago and has since built an operating presence around reliable electricity, local training and community work. In a country scattered across thousands of islands, dependable power is not some decorative...

Continue Reading
Vector's Peptide Pact Needs Proof Before Any Payday

Updated Category News Views 194

A famous orthopedic name can open doors, but it cannot manufacture clinical evidence. That is the plain reality behind Vector Science and Therapeutics' new collaboration with the Andrews Research & Education Foundation. Dr. James Andrews carries enormous credibility in sports medicine, earned across more than five decades of work. For Vector, that association matters. For...

Continue Reading

Top 5 Most Recently Viewed Articles

Appian Partners with Children's National to Elevate Healthcare

Updated Category News Views 87

Appian Teams Up with Children’s National Hospital Appian, known for its cutting-edge software solutions, is excited to share its new collaboration with Children’s National Hospital, one of the top names in pediatric healthcare. This partnership aims to raise awareness and gather essential resources for children's health. Appian is dedicated to enhancing the healthcare...

Continue Reading
Deutsche Bank Predicts ECB Rate Cuts Amid Falling Inflation

Updated Category News Views 101

Deutsche Bank dropped a prediction back in late 2023 that the European Central Bank (ECB) was gearing up for interest rate cuts this October. Traders perked up when they caught wind of unexpected dips in inflation figures from the eurozone noted earlier that September. Why the Cut? Inflation Insights Unpacked Analysts at Deutsche Bank, led by chief economist Mark Wall,...

Continue Reading
Vipshop's Financial Performance Analysis for 2024 Revealed

Updated Category News Views 390

Vipshop's Financial Insights for 2024 Vipshop Holdings Limited (NYSE: VIPS), a prominent online discount retailer in the Chinese market, has recently shared its unaudited financial results for the quarter and full year that concluded on December 31, 2024. Despite encountering challenges over the previous year, Vipshop's performance indicates resilience and potential...

Continue Reading
Boston University and Infocap Partner for Digital Transformation

Updated Category News Views 207

Boston University's Digital Business Institute Partners with Infocap BOSTON--The Digital Business Institute (DBI) at Boston University Questrom School of Business and Infocap AI Corp, a leader in human-centric automation, have announced a strategic partnership aimed at revolutionizing digital transformation across the banking sector. This collaboration is particularly...

Continue Reading
Disclosure and Investment Position Overview for Keywords Studios

Updated Category News Views 116

Understanding Disclosure and Investment Positions In the complex world of stock market investments, transparency is crucial. This is especially true for organizations involved with Keywords Studios PLC, a leading player in the gaming services sector. This article seeks to shed light on the recent disclosures and key investments associated with this prominent company. Key...

Continue Reading